Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCT08V)

Drug Name

Domagrozumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Duchenne dystrophy	8C70	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Growth/differentiation factor 8 (GDF-8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY2495655	DMM5JAN	Disuse muscle atrophy	8B61	Phase 2	[2]
AMG 745	DMFXN2T	Muscle atrophy	FB32.Y	Phase 2	[3]
PF-06252616	DMQLZOF	Duchenne dystrophy	8C70	Phase 2	[2]
SAR391786	DMS1YPZ	Muscle atrophy	FB32.Y	Phase 2	[4]
ACE-031	DMZ8PY0	Duchenne dystrophy	8C70	Phase 2	[5]
Stamulumab	DMBCIXL	Duchenne dystrophy	8C70	Phase 1/2	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Growth/differentiation factor 8 (GDF-8)	TTSWPH8	GDF8_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.
3	The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011 September; 2(3): 143-151.
4	Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010 Mar;10(1):56-63.
5	A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013 Mar;47(3):416-23.